iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Sees Significant Growth in Short Interest

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 218,618 shares, a growth of 847.2% from the September 15th total of 23,081 shares. Currently, 2.9% of the shares of the stock are short sold. Based on an average trading volume of 209,979 shares, the short-interest ratio is currently 1.0 days.

iShares Genomics Immunology and Healthcare ETF Price Performance

Shares of NYSEARCA IDNA traded up $1.75 during midday trading on Friday, reaching $42.17. 151,574 shares of the stock traded hands, compared to its average volume of 67,732. The company’s 50 day moving average is $38.99 and its 200 day moving average is $33.57. iShares Genomics Immunology and Healthcare ETF has a one year low of $23.90 and a one year high of $43.44. The stock has a market capitalization of $314.17 million, a PE ratio of 14.76 and a beta of 0.94.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

A hedge fund recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Anchor Investment Management LLC bought a new position in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 2,898 shares of the company’s stock, valued at approximately $98,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.